JP2020514363A - 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ - Google Patents

腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ Download PDF

Info

Publication number
JP2020514363A
JP2020514363A JP2019550705A JP2019550705A JP2020514363A JP 2020514363 A JP2020514363 A JP 2020514363A JP 2019550705 A JP2019550705 A JP 2019550705A JP 2019550705 A JP2019550705 A JP 2019550705A JP 2020514363 A JP2020514363 A JP 2020514363A
Authority
JP
Japan
Prior art keywords
antibody
seq
cells
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514363A5 (enExample
Inventor
アンヌ グビエ
アンヌ グビエ
パスカル メルヒールス
パスカル メルヒールス
ジョセフィン サリム
ジョセフィン サリム
コルソ ベアトリス ゴイエンチェア
コルソ ベアトリス ゴイエンチェア
ケヴィン モウルダー
ケヴィン モウルダー
セルジオ ケサダ
セルジオ ケサダ
カール ペッグス
カール ペッグス
バルガス フレデリック アルセ
バルガス フレデリック アルセ
イザベル ソロモン
イザベル ソロモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020514363(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1710879.6A external-priority patent/GB201710879D0/en
Priority claimed from GBGB1714429.6A external-priority patent/GB201714429D0/en
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2020514363A publication Critical patent/JP2020514363A/ja
Publication of JP2020514363A5 publication Critical patent/JP2020514363A5/ja
Priority to JP2024009215A priority Critical patent/JP2024050684A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
JP2019550705A 2017-03-17 2018-03-13 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ Pending JP2020514363A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024009215A JP2024050684A (ja) 2017-03-17 2024-01-25 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17161717 2017-03-17
EP17161717.8 2017-03-17
GB1710879.6 2017-07-06
GBGB1710879.6A GB201710879D0 (en) 2017-07-06 2017-07-06 Methods and compounds for tumour-specific cell depletion
GB1714429.6 2017-09-07
GBGB1714429.6A GB201714429D0 (en) 2017-09-07 2017-09-07 Compounds and methods for tumour-specific cell depletion
PCT/EP2018/056312 WO2018167104A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024009215A Division JP2024050684A (ja) 2017-03-17 2024-01-25 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５

Publications (2)

Publication Number Publication Date
JP2020514363A true JP2020514363A (ja) 2020-05-21
JP2020514363A5 JP2020514363A5 (enExample) 2021-04-30

Family

ID=61655786

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019550705A Pending JP2020514363A (ja) 2017-03-17 2018-03-13 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５
JP2024009215A Pending JP2024050684A (ja) 2017-03-17 2024-01-25 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024009215A Pending JP2024050684A (ja) 2017-03-17 2024-01-25 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５

Country Status (26)

Country Link
US (1) US11879014B2 (enExample)
EP (1) EP3596123B1 (enExample)
JP (2) JP2020514363A (enExample)
KR (1) KR20190130137A (enExample)
CN (1) CN110869388B (enExample)
AU (1) AU2018233976B2 (enExample)
BR (1) BR112019017017A2 (enExample)
CA (1) CA3056506A1 (enExample)
CL (1) CL2019002624A1 (enExample)
CR (1) CR20190477A (enExample)
DK (1) DK3596123T3 (enExample)
ES (1) ES2975063T3 (enExample)
FI (1) FI3596123T3 (enExample)
HR (1) HRP20240469T1 (enExample)
HU (1) HUE065999T2 (enExample)
IL (1) IL269081A (enExample)
LT (1) LT3596123T (enExample)
MX (1) MX2019010974A (enExample)
MY (1) MY208220A (enExample)
NZ (1) NZ756984A (enExample)
PE (1) PE20191812A1 (enExample)
PL (1) PL3596123T3 (enExample)
RS (1) RS65351B1 (enExample)
SG (1) SG11201908578YA (enExample)
SI (1) SI3596123T1 (enExample)
WO (1) WO2018167104A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515565A (ja) * 2018-03-13 2021-06-24 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011592A1 (en) 2015-07-13 2017-01-19 Modular Genetics, Inc. Generation of acyl alcohols
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
JP7619941B2 (ja) * 2018-11-14 2025-01-22 アイバイオ， インク． Ｃｄ２５抗体
JP7695881B2 (ja) * 2018-11-14 2025-06-19 アイバイオ， インク． 操作されたｃｄ２５ポリペプチドおよびその使用
US20220251232A1 (en) * 2019-05-20 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
ES3037019T3 (en) * 2019-06-10 2025-09-26 Shandong Boan Biotechnology Co Ltd Anti-cd25 antibody and application thereof
BR112022020521A2 (pt) 2020-04-10 2023-03-07 Rakuten Medical Inc Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos
TW202144429A (zh) 2020-05-14 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
WO2022106663A1 (en) * 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
EP4247497A1 (en) * 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
EP4288100A1 (en) * 2021-02-02 2023-12-13 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
CA3209636A1 (en) 2021-03-01 2022-09-09 F. Hoffmann-La Roche Ag Novel biomarkers and uses thereof
CN117916266A (zh) 2021-09-02 2024-04-19 弗哈夫曼拉罗切有限公司 用于治疗aml的抗体
CN119095621A (zh) 2022-04-26 2024-12-06 弗哈夫曼拉罗切有限公司 用于治疗癌症的包括Fas轴拮抗剂和T-reg细胞消耗剂拮抗剂的联合疗法
CN115181182B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种人源化的抗cd25的单域抗体及其应用
WO2024006965A1 (en) * 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd25-specific antibodies and uses thereof
WO2024006961A1 (en) 2022-07-01 2024-01-04 Neoleukin Therapeutics, Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN118240080A (zh) * 2022-12-22 2024-06-25 深圳市福元生物科技有限公司 一种cd25单域抗体、人源化抗体、及制备方法
EP4662238A1 (en) 2023-02-06 2025-12-17 F. Hoffmann-La Roche AG Combination therapy and uses thereof
CN116087499B (zh) * 2023-02-20 2023-10-31 深圳裕康医学检验实验室 一种癌样本的染色方法及试剂盒
CN120314588B (zh) * 2025-05-21 2025-10-17 成都蓉生药业有限责任公司 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013514778A (ja) * 2009-12-21 2013-05-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ＦｃγＲマウス

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
CA2656700A1 (en) 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
EP2423231A3 (en) 2006-08-18 2012-05-30 Novartis AG PRLR-specific antibody and uses thereof
RU2391401C2 (ru) 2008-02-12 2010-06-10 Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JP5746183B2 (ja) 2009-09-22 2015-07-08 プロビオゲン アーゲー 特定のグリカン構造を含有する分子を生成する方法
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
RU2598711C2 (ru) 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения
CA2904532A1 (en) 2013-03-15 2014-09-18 Abbvie Biotechnology Ltd. Anti-cd25 antibodies and their uses
CA2904527A1 (en) 2013-03-15 2014-09-18 Abbvie Biotechnology Ltd. Anti-cd25 antibodies and their uses
DK2970486T3 (en) * 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
BR112018070636A2 (pt) 2016-04-07 2019-02-05 Cancer Research Technology Limited método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
JP2019532996A (ja) 2016-11-08 2019-11-14 デリニア，インコーポレーテッド 自己免疫疾患を処置するためのｉｌ−２変異体
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
MA51992A (fr) 2018-03-13 2021-06-23 Cancer Research Tech Ltd Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013514778A (ja) * 2009-12-21 2013-05-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ＦｃγＲマウス

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF IMMUNOTOXICOLOGY, vol. 5, JPN6022013061, 2008, pages 235 - 248, ISSN: 0005332449 *
JOURNAL OF ONCOLOGY, vol. Article ID 963037, JPN6022013062, 2009, pages 1 - 8, ISSN: 0005332448 *
薬剤学, (2012), vol. 72, no. 5, JPN6023039391, 2012, pages 276 - 282, ISSN: 0005332450 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515565A (ja) * 2018-03-13 2021-06-24 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP2021515566A (ja) * 2018-03-13 2021-06-24 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP2021516974A (ja) * 2018-03-13 2021-07-15 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP2021516973A (ja) * 2018-03-13 2021-07-15 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP2021516976A (ja) * 2018-03-13 2021-07-15 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP2021516975A (ja) * 2018-03-13 2021-07-15 タスク セラピューティクス リミテッド 抗ｃｄ２５抗体剤
JP2021533726A (ja) * 2018-03-13 2021-12-09 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP7451415B2 (ja) 2018-03-13 2024-03-18 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP7451414B2 (ja) 2018-03-13 2024-03-18 タスク セラピューティクス リミテッド 抗ｃｄ２５抗体剤
JP7474701B2 (ja) 2018-03-13 2024-04-25 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５抗体
JP7563978B2 (ja) 2018-03-13 2024-10-08 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP7563979B2 (ja) 2018-03-13 2024-10-08 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP7565797B2 (ja) 2018-03-13 2024-10-11 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５

Also Published As

Publication number Publication date
LT3596123T (lt) 2024-03-25
PL3596123T3 (pl) 2024-06-24
US20200010554A1 (en) 2020-01-09
CR20190477A (es) 2020-01-07
MX2019010974A (es) 2020-08-03
SG11201908578YA (en) 2019-10-30
AU2018233976B2 (en) 2025-03-20
SI3596123T1 (sl) 2024-05-31
WO2018167104A1 (en) 2018-09-20
PE20191812A1 (es) 2019-12-26
FI3596123T3 (fi) 2024-04-17
EP3596123A1 (en) 2020-01-22
IL269081A (en) 2019-11-28
BR112019017017A2 (pt) 2020-04-14
CA3056506A1 (en) 2018-09-20
AU2018233976A1 (en) 2019-10-31
KR20190130137A (ko) 2019-11-21
HUE065999T2 (hu) 2024-06-28
JP2024050684A (ja) 2024-04-10
CL2019002624A1 (es) 2020-04-03
HRP20240469T1 (hr) 2024-07-19
DK3596123T3 (da) 2024-02-26
CN110869388A (zh) 2020-03-06
MY208220A (en) 2025-04-24
EP3596123B1 (en) 2024-01-10
RS65351B1 (sr) 2024-04-30
ES2975063T3 (es) 2024-07-03
NZ756984A (en) 2025-08-29
US11879014B2 (en) 2024-01-23
CN110869388B (zh) 2024-09-20

Similar Documents

Publication Publication Date Title
AU2018233976B2 (en) Fc-optimized anti-CD25 for tumour specific cell depletion
US11919960B2 (en) Anti-CD25 antibody agents
WO2022136649A1 (en) Non-blocking human ccr8 binders
WO2022003156A1 (en) Ccr8 non-blocking binders
WO2022136647A1 (en) Human ccr8 binders
JP2020525517A (ja) 腫瘍特異的細胞枯渇のための化合物及び方法
US20240018248A1 (en) An ltbr agonist in combination therapy against cancer
EP4267621A1 (en) Murine cross-reactive human ccr8 binders
US20250333526A1 (en) Antibodies capable of binding to ox40, variants thereof and uses thereof
RU2839380C1 (ru) Fc-оптимизированные антитела к cd25 для истощения опухолеспецифических клеток
HK40016585A (en) Fc-optimized anti-cd25 for tumor specific cell depletion
CN120813377A (zh) Btn3a活化抗体和免疫检查点抑制剂的组合
HK40016585B (zh) 用於肿瘤特异性细胞消耗的fc优化的抗cd25

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240308

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240531